Core Viewpoint - The company Xingqi Eye Pharmaceutical (300573) has maintained a strong position in the national medical insurance drug list, which is expected to positively impact its long-term business performance [1]. Group 1: Stock Performance - As of December 8, 2025, Xingqi Eye Pharmaceutical's stock closed at 73.09 yuan, up 0.16% from the previous trading day [1]. - The stock opened at 73.19 yuan, reached a high of 74.18 yuan, and a low of 72.97 yuan, with a trading volume of 4.49 billion yuan and a turnover rate of 3.23% [1]. Group 2: National Medical Insurance Drug List - The National Healthcare Security Administration has included 39 products from Xingqi Eye Pharmaceutical in the 2025 National Basic Medical Insurance, Maternity Insurance, and Work Injury Insurance Drug List, with 8 in Category A and 31 in Category B, and no products being removed [1]. - Key products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Wash, and Sodium Hyaluronate Eye Drops continue to be included, while the restriction on the use of Gatifloxacin Eye Gel has been lifted [1]. - The new drug list will take effect on January 1, 2026, and is expected to have a long-term positive impact on the company's operating performance, although there is no significant short-term impact [1].

Core Viewpoint - The announcement indicates that the company, Xingqi Eye Pharmaceutical, has successfully maintained its products in the National Medical Insurance Drug List, which is crucial for its market position and revenue stability [1] Group 1: Company Products - A total of 39 products from the company will continue to be included in the National Medical Insurance Drug List, with 8 classified as Category A and 31 as Category B [1] - Key products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops remain in the National Medical Insurance List, indicating strong product performance and market acceptance [1] - The company has not experienced any product withdrawals from the National Medical Insurance Drug List, which reflects positively on its product portfolio and regulatory compliance [1]

Core Viewpoint - The company Xingqi Eye Medicine (300573) announced that 39 of its products will continue to be included in the 2025 National Medical Insurance Catalog, with no products being removed from the catalog [1] Group 1 - The company has 39 products included in the 2025 National Medical Insurance Catalog, consisting of 8 Class A and 31 Class B products [1] - Specific products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops will continue to be covered [1] - The statement regarding the use of Gatifloxacin Eye Gel as a "second-line medication" has been removed from the catalog notes [1] Group 2 - The inclusion status of the company's other products in the 2025 National Medical Insurance Catalog remains unchanged from the 2024 catalog [1]

Core Viewpoint - The company, Xingqi Eye Pharmaceutical, announced that 39 of its products will continue to be included in the National Medical Insurance Drug List, with no products being removed [1] Group 1: Product Inclusion - The 39 products consist of 8 Class A and 31 Class B drugs [1] - Notable products such as Cyclosporine Eye Drops (II), Compound Electrolyte Eye Irrigation Solution, and Sodium Hyaluronate Eye Drops remain in the National Medical Insurance Directory [1] Group 2: Future Implications - The new version of the National Medical Insurance Drug List will take effect on January 1, 2026 [1] - The short-term impact on the company's operating performance is expected to be minor [1] - Future sales of the drugs may be influenced by changes in pharmaceutical industry policies and market conditions, indicating uncertainty [1]

Core Viewpoint - In 2024, Xingqi Eye Medicine (300573.SZ) demonstrated strong growth in the ophthalmic prescription drug sector, achieving significant revenue and profit increases, solidifying its leading position in the industry [1][2]. Financial Performance - The company reported a total revenue of 1.943 billion yuan in 2024, representing a year-on-year increase of 32.42% [2]. - Net profit reached 338 million yuan, up 40.84% year-on-year, with a non-recurring net profit growth of 44.54% to 348 million yuan [2]. - The net cash flow from operating activities was 417 million yuan, reflecting a 31.31% increase [2]. Product Performance - The eye drop segment showed remarkable growth, generating 1.366 billion yuan in revenue, a 106.08% increase, and accounting for 70.3% of total revenue [2]. - Key products driving this growth included low-concentration atropine eye drops (brand name "Mei Ou Pin") and cyclosporine eye drops (II) [2]. Investor Returns - The company proposed a profit distribution plan, intending to distribute a cash dividend of 10 yuan per 10 shares, totaling 175 million yuan, and a capital reserve conversion of 4 shares for every 10 shares held [3]. Production and Quality Management - The company focused on enhancing production and quality management, optimizing resource allocation, and upgrading production facilities to improve efficiency and support smart factory initiatives [4]. - Quality management improvements included passing various regulatory inspections and certifications, indicating a stable and effective quality management system [5]. Research and Development - In 2024, R&D expenses reached 221 million yuan, a 31.90% increase, with the company holding 66 invention patents [6]. - Significant progress was made in R&D, including the approval of clinical trials for new products aimed at treating common eye diseases [6][7]. Future Outlook - For 2025, the company reported a revenue of 536 million yuan in Q1, a 53.24% increase, and a net profit of 146 million yuan, up 319.86% year-on-year [8]. - The company outlined four key operational plans for 2025: production and quality centers, product R&D, marketing, and internal control management, with a focus on unmet clinical needs and innovation [9].